Detailed Information on Publication Record
2019
Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs
MUNSTER, Lukas, Michaela FOJTŮ, Zdenka CAPAKOVA, Tomáš VACULOVIČ, Michaela TVRDOŇOVÁ et. al.Basic information
Original name
Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs
Authors
MUNSTER, Lukas (203 Czech Republic), Michaela FOJTŮ (203 Czech Republic, belonging to the institution), Zdenka CAPAKOVA (203 Czech Republic), Tomáš VACULOVIČ (203 Czech Republic, belonging to the institution), Michaela TVRDOŇOVÁ (203 Czech Republic, belonging to the institution), Ivo KURITKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution) and Jan VICHA (203 Czech Republic)
Edition
Biomacromolecules, Washington, American Chemical Society, 2019, 1525-7797
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10608 Biochemistry and molecular biology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.092
RIV identification code
RIV/00216224:14110/19:00107804
Organization unit
Faculty of Medicine
UT WoS
000464248300015
Keywords in English
NMR CHEMICAL-SHIFTS; DENSITY-FUNCTIONAL THEORY; RELATIVISTIC DOUBLE-ZETA; HYALURONIC-ACID; DIALDEHYDE CELLULOSE; TRIPLE-ZETA; BASIS-SETS; PT-195 NMR; CISPLATIN; PERIODATE
Tags
International impact, Reviewed
Změněno: 31/3/2020 22:07, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug binding efficiency (>90%) and drug loading capacity (up to 50 wt %), while retaining good aqueous solubility. The adjustable molecular weight of the DCC together with variances in drug feeding ratio allows to optimize cisplatin release profiles from delayed (<2% of cisplatin released during 6 h) to classical burst release with more than 60% of cisplatin released after 24 h. The release rates are also pH-dependent (up to 2 times faster release at pH 5.5 than at pH 7.4), which allows to exploit the acidic nature of tumor microenvironment. Extensive in vitro studies were performed on eight different cell lines for two cisplatin-DCC conjugates with different release profiles. In comparison with free cisplatin, both cisplatin-DCC conjugates demonstrated considerably lower cytotoxicity toward healthy cells. Conjugates with burst release profiles were found more effective against prostate cell lines, while DCC conjugates with slower release were more cytotoxic against ovarian and lung carcinoma cell lines. In vivo studies indicated a significantly longer survival rate, a reduction in tumor volume, and a higher accumulation of platinum in tumors of mice treated with the cisplatin-DCC conjugate in comparison to those treated by free cisplatin.
Links
GA16-05961S, research and development project |
| ||
LM2015043, research and development project |
| ||
LM2015085, research and development project |
| ||
MUNI/A/1255/2018, interní kód MU |
| ||
MUNI/A/1553/2018, interní kód MU |
|